Thermo Fisher Scientific Inc. $TMO Shares Acquired by Fortitude Advisory Group L.L.C.

Fortitude Advisory Group L.L.C. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,058 shares of the medical research company’s stock after buying an additional 142 shares during the period. Fortitude Advisory Group L.L.C.’s holdings in Thermo Fisher Scientific were worth $429,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. CBIZ Investment Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $31,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Stock Up 3.6%

TMO stock opened at $543.88 on Friday. The company’s 50 day simple moving average is $482.58 and its 200-day simple moving average is $447.27. The firm has a market capitalization of $205.37 billion, a PE ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.